GA3OX3 Antibody
Description
GA3 Antibody: Target and Specificity
The GA3 monoclonal antibody was developed to study lineage-restricted glycosylation patterns on leukosialin (Gp105), a 105 kDa membrane protein expressed during erythroid differentiation .
Key Features of GA3 Antibody:
| Parameter | Detail |
|---|---|
| Target Antigen | Leukosialin (Gp105), a sialylated glycoprotein in the erythroid lineage |
| Epitope Dependency | Requires terminal O-linked sialic acid (neuraminidase-sensitive) |
| Cellular Specificity | Restricted to proerythroblasts and erythroid precursors in bone marrow |
| Cross-Reactivity | Minor reactivity with CD3+, CD4+ T-lymphocytes |
Mechanism of Action:
GA3 binds to an O-glycosylated epitope on leukosialin, which is absent in other hematopoietic lineages. This specificity arises from lineage-restricted glycosylation patterns during erythroid maturation .
Glycosylation Dependency and Functional Implications
GA3’s binding is abolished by neuraminidase treatment (which removes sialic acid), but unaffected by tunicamycin (an N-linked glycosylation inhibitor) . This confirms that GA3 recognizes an O-linked glycan structure critical for its epitope.
Experimental Evidence:
| Experiment | Result |
|---|---|
| Neuraminidase treatment | Abolishes GA3 binding to K562 erythroleukemic cells |
| Tunicamycin treatment | No effect on GA3 binding |
| Cocapping with L10 (anti-sialophorin) | Demonstrates GA3 binds to the same leukosialin molecule as L10 |
Biological Relevance:
GA3 serves as a marker for early erythroid precursors, appearing before glycophorin A during differentiation. This makes it valuable for studying erythroid lineage commitment and glycosylation-dependent cell recognition .
Potential Applications and Limitations
While GA3 has been used in basic research, no clinical or therapeutic applications are documented in the provided sources. Its utility lies in:
-
Tracking erythroid development in bone marrow and peripheral blood.
-
Studying glycosylation mechanisms in immune cell differentiation.
Limitations:
-
Restricted to erythroid lineage (unlike pan-hematopoietic markers like CD34).
-
Cross-reactivity with a subset of T-cells complicates lineage-specific analysis .
GA3OX3 Antibody: Clarifications and Gaps
The term "GA3OX3" does not appear in any indexed literature or clinical databases (e.g., PubMed, Antibody Society registries) . Possible explanations include:
-
Nomenclature Error: A misreference to GA3 or a related antibody.
-
Emerging Compound: A novel variant or conjugate not yet published.
-
Proprietary Designation: A non-standard naming convention from a specific laboratory or company.
Recommendation: Verify the correct nomenclature or consult primary sources (e.g., unpublished studies, institutional repositories) for further details.
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- Genetic studies have revealed that mutant plants lacking both GA3ox1 and GA3ox3 functions exhibit defects in stamen and petal development. This finding underscores the significance of these two genes in GA production within the flower.
- Further evidence supporting the role of GA3OX3 in reproductive development comes from the study published in PMID: 18310462, which demonstrates the importance of GA3ox1 and GA3ox3 for GA production in the flower.
